Quantcast

Latest treatment of multiple sclerosis Stories

2014-06-26 12:29:42

LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Multiple Sclerosis -- KOL Insight and Consensus Outlook Moduleshttp://www.reportbuyer.com/pharma_healthcare/diseases/multiple_sclerosis_kol_insight_consensus_outlook_modules.html IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen's Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market...

2014-06-25 12:30:05

MISSISSAUGA, ON, June 25, 2014 /CNW/ - Biogen Idec Canada announces today that TECFIDERA(TM) (dimethyl fumarate) is now available for reimbursement in British Columbia (B.C.) through B.C. PharmaCare. TECFIDERA(TM) is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERA(TM) is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the progression of disability.(1) "TECFIDERA is...

2014-06-12 12:30:07

Current Neurologist-Reported Patient Share for Tecfidera Exceeds that of Genzyme's Aubagio and Novartis's Gilenya Combined, According to Findings from Decision Resources Group BURLINGTON, Mass., June 12, 2014 /PRNewswire/ -- Decision Resources Group finds that, within one year of commercial availability, 100 percent of surveyed U.S. neurologists have prescribed Biogen Idec's Tecfidera to at least one of their multiple sclerosis (MS) patients, far surpassing the one-year trial rate for...

2014-05-27 08:28:11

NESS ZIONA, Israel, May 27, 2014 /PRNewswire/ -- Mapi Pharma Ltd. ("Mapi" or the "Company"), a developer of high-barrier to entry and high value-added generic drugs, announced today that its US patent for the company's Glatiramer Acetate Depot has been extended until December 2030. The notice of allowance for US Patent Application No. 13/258,808 entitled Depot Systems Comprising Glatiramer or Pharmacologically Acceptable Salt Thereof, also awarded additional claims to...

2014-05-27 08:27:32

MISSISSAUGA, ON, May 27, 2014 /CNW/ - Biogen Idec Canada announces today that TECFIDERA(TM) (dimethyl fumarate) is now available for reimbursement in Ontario through the Ontario Public Drugs Program's (OPDP) Exceptional Access Program (EAP), as indicated in the upcoming May 29, 2014, Edition No. 42, Ontario Drug Benefit Formulary/Comparative Index. TECFIDERA(TM) is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERA(TM) is indicated as...

2014-05-01 12:32:03

- Consistent effects seen across key MRI measures of disease activity; Effects were sustained beyond two-year pivotal MS studies - - Approximately 80 percent of patients treated with Lemtrada did not receive a third course of treatment in the first year of the extension - CAMBRIDGE, MA, May 1, 2014 /CNW/ - Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced new magnetic resonance imaging (MRI) data from the Lemtrada (alemtuzumab) clinical development program. In Lemtrada...

2014-04-15 23:02:24

Crowdfunding Gets FDA-Approved Stem Cell Trial Off To Fast Start New York, NY (PRWEB) April 15, 2014 The Tisch MS Research Center of New York (Tisch MSRCNY) today announced that they surpassed their campaign goal on Indiegogo.com to raise funds for their FDA-Approved Phase I Clinical Stem Cell Trial. The funding will be directly applied to the study and stem cell research at Tisch MSRCNY. The target of $300K was met and surpassed within the allotted four weeks of the campaign's launch...

2014-04-11 16:21:36

DUBLIN, April 11, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/btp9ds/global_multiple) has announced the addition of the "Global Multiple Sclerosis (MS) Therapeutics Market Report" [http://www.researchandmarkets.com/research/btp9ds/global_multiple ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The analysts forecast the Global Multiple Sclerosis (MS) Therapeutics market to grow at...

2014-03-18 12:31:24

Patients Rapidly Shifting to New Oral Therapies PHILADELPHIA, March 18, 2014 /PRNewswire/ -- Health Union, LLC announced today on its website http://multiplesclerosis.net the topline results from its "2014 MS in America" survey of over 5,000 multiple sclerosis (MS) patients. This survey is one of the largest of its kind ever conducted. Symptoms - Diagnosis - Treatment Gap Even though scientific evidence[i] shows that early treatment can reduce the risk of disease progression,...

2014-03-17 23:04:21

Crowdfunding Site Targeted to Raise $300K for FDA-Approved Adult Stem Cell Trial New York, NY (PRWEB) March 17, 2014 The Tisch MS Research Center of New York (Tisch MSRCNY) today announced that they have launched a dedicated campaign on Indiegogo to raise funds for their FDA-Approved Phase I Clinical Stem Cell Trial. The non-profit research center aims to raise $300K to be directly applied to the first twenty patients selected to participate in the clinical trial. “We are excited to...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.